Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Royal Brompton & Harefield NHS Foundation Trust · National Institute for Health and Care Research · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
558
total citations
- FWCI
- 45.55
- Percentile
- 100%
- References
- 28
Citations per year
Authors
168- AUAthol U. WellsCorresponding
Royal Brompton & Harefield NHS Foundation Trust, National Institute for Health and Care Research
- KRKevin R. Flaherty
University of Michigan
- KKKevin K. Brown
National Jewish Health, University of Colorado Denver
- YIYoshikazu Inoue
NHO Kinki Chuo Chest Medical Center
- ADAnand Devaraj
Royal Brompton & Harefield NHS Foundation Trust, Imperial College London
Topics & keywords
Topics
Keywords
- Medicine
- Nintedanib
- Interstitial lung disease
- Placebo
- Lung
- Idiopathic pulmonary fibrosis
- Internal medicine
- Subgroup analysis
No related works found for this paper.